

ASX RELEASE

3 March 2023

KAZIA THERAPEUTICS LIMITED (ASX: KZA; NASDAQ: KZIA) – CLEANSING NOTICE


This notice is given by Kazia Therapeutics Limited (**Kazia**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

On 3 March 2023, Kazia has issued 23,691,045 fully paid ordinary shares (**New Shares**) to existing shareholders at an issue price of \$0.11 per New Share, as foreshadowed in its Share Purchase Plan Offer booklet announced to ASX on 19 January 2023.

In accordance with section 708A(6) of the Corporations Act, Kazia advises that:

- (a) the New Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, Kazia has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to Kazia; and
 - (ii) section 674 of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is "excluded information" within the meaning of sections 708A(7) or 708A(8) of the Corporations Act.

Yours sincerely



Anna Sandham
Company Secretary

Board of Directors

Mr Iain Ross Chairman, Non-Executive Director
Mr Bryce Carmine Non-Executive Director
Mr Steven Coffey Non-Executive Director
Dr James Garner Chief Executive Officer, Managing Director